An open, randomised phase I/II dose escalation study evaluating the safety and tolerability, pharmacokinetics, antigenicity and efficacy of Iodine-131-Kab201 when given intra-arterially or intravenously in patients with surgically unresectable pancreatic ductal adenocarcinoma

Authors
Category Primary study
Registry of TrialsISRCTN registry
Year 2005
This article has no abstract
Epistemonikos ID: 37ffc1d90dd5c632acb044f0ab899b597c1aa5dd
First added on: Jan 17, 2025